mirtazapine has been researched along with Fatigue in 5 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Primary care patients with a major depressive disorder and 17-item Hamilton Rating Scale for Depression (17-HAM-D) score >18 were randomized to 24 weeks of treatment with mirtazapine 30-45 mg/day (n=99) or paroxetine 20-30 mg/day (n=98)." | 5.10 | A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. ( Angus, M; Crawford, GM; Hamilton, L; Wade, A; Wilson, R, 2003) |
| "Mirtazapine is a third-generation antidepressant with a dual mode of action." | 2.72 | Intravenous mirtazapine is safe and effective in the treatment of depressed inpatients. ( Egger, C; Eichberger, G; Hinterhuber, H; Hofmann, P; Kasper, S; Konstantinidis, A; Mühlbacher, M; Nickel, M; Nimmerrichter, A; Schubert, H; Stuppaeck, C, 2006) |
| "Pancreatic cancer is the tumour related to higher rates of depression." | 1.62 | Depression preceding the diagnosis of pancreatic cancer. ( Carvalho, A; Esperto, H; Ferreira, M; Moreira, H, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira, M | 1 |
| Moreira, H | 1 |
| Esperto, H | 1 |
| Carvalho, A | 1 |
| Rizo, C | 1 |
| Deshpande, A | 1 |
| Ing, A | 1 |
| Seeman, N | 1 |
| Wade, A | 1 |
| Crawford, GM | 1 |
| Angus, M | 1 |
| Wilson, R | 1 |
| Hamilton, L | 1 |
| Wingen, M | 1 |
| Bothmer, J | 1 |
| Langer, S | 1 |
| Ramaekers, JG | 1 |
| Mühlbacher, M | 1 |
| Konstantinidis, A | 1 |
| Kasper, S | 1 |
| Eichberger, G | 1 |
| Hinterhuber, H | 1 |
| Hofmann, P | 1 |
| Nimmerrichter, A | 1 |
| Schubert, H | 1 |
| Egger, C | 1 |
| Nickel, M | 1 |
| Stuppaeck, C | 1 |
3 trials available for mirtazapine and Fatigue
| Article | Year |
|---|---|
A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepress | 2003 |
Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial.
Topics: Adult; Affect; Antidepressive Agents, Tricyclic; Automobile Driving; Circadian Rhythm; Citalopram; C | 2005 |
Intravenous mirtazapine is safe and effective in the treatment of depressed inpatients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Fatigue; Fema | 2006 |
2 other studies available for mirtazapine and Fatigue
| Article | Year |
|---|---|
Depression preceding the diagnosis of pancreatic cancer.
Topics: Abdominal Pain; Antidepressive Agents; Depression; Drug Therapy; Fatigue; Female; Humans; Middle Age | 2021 |
A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Data Col | 2011 |